Fondazione Italiana Fegato-Onlus, Bldg. Q, AREA Science Park, ss14, Km 163.5, Basovizza, 34149 Trieste, Italy.
Faculty of Medicine, University of Hasanuddin, Makassar 90245, Indonesia.
Int J Mol Sci. 2021 Jun 9;22(12):6223. doi: 10.3390/ijms22126223.
Following the increase in life expectancy, the prevalence of Parkinson's disease (PD) as the most common movement disorder is expected to rise. Despite the incredibly huge efforts in research to find the definitive biomarker, to date, the diagnosis of PD still relies mainly upon clinical symptoms. A wide range of treatments is available for PD, mainly alleviating the clinical symptoms. However, none of these current therapies can stop or even slow down the disease evolution. Hence, disease-modifying treatment is still a paramount unmet medical need. On the other side, bilirubin and its enzymatic machinery and precursors have offered potential benefits by targeting multiple mechanisms in chronic diseases, including PD. Nevertheless, only limited discussions are available in the context of neurological conditions, particularly in PD. Therefore, in this review, we profoundly discuss this topic to understand bilirubin's therapeutical potential in PD.
随着预期寿命的延长,帕金森病(PD)作为最常见的运动障碍疾病的患病率预计将会上升。尽管在寻找明确的生物标志物方面做出了难以置信的巨大努力,但迄今为止,PD 的诊断仍然主要依赖于临床症状。有广泛的治疗方法可用于 PD,主要是缓解临床症状。然而,这些目前的治疗方法都不能阻止甚至减缓疾病的进展。因此,疾病修饰治疗仍然是一个亟待满足的医学需求。另一方面,胆红素及其酶机制和前体通过靶向包括 PD 在内的慢性疾病中的多种机制,提供了潜在的益处。然而,在神经疾病的背景下,只有有限的讨论,特别是在 PD 中。因此,在这篇综述中,我们深入讨论了这个话题,以了解胆红素在 PD 中的治疗潜力。